ACURA Award

2024 Call for Proposals Now Open!

Pour la version française, cliquez ici.

The ACURA (AbbVie – CARO Uro-Oncologic Radiation Award) program has enabled radiation oncology clinicians and researchers from across the country to make significant advances in the treatment of prostate cancer, thanks to the enduring partnership between CARO and AbbVie.

AbbVie and CARO are pleased to announce the Annual ACURA Competition for $85,000 in grant monies for prostate cancer research. 2 of 5 ACURA Awards will be granted to young investigators (5 years or less, of practice as an attending staff).

Award Eligibility

  1. The focus of the research should be prostate cancer.
  2. The competition will be open to clinical or non-clinical projects.
  3. The Principal Investigator must be a CARO member in good standing at the time of application.
  4. Non-CARO members may participate in a submission.
  5. Funds requested will be limited to a maximum of $17,000 per submission.
  6. Each applicant will be limited to one submission.
  7. Each submission must be sent via e-mail to the CARO office using the template; no application shall be accepted if it is not within the application template.
  8. Each application must contain a clear statement of any other agencies to which the proposal has been sent. Other support expected or received should be documented.
  9. Where a centre has equipment that can be used in support of the study, requests for such funding should not be included in the application (e.g. CT-simulator scans, statistics support, if that is usually available within the centre, etc.)
  10. Proposals will be reviewed and recommended for funding on the basis of high scientific merit, feasibility, and relevance to Canadian Radiation Oncology.
  11. Funds successfully awarded must be spent within Canada, but proposals may involve more than one centre. Candidates must identify a host institution in Canada that will receive and administer the funds.
  12. All applicants who have received awards from CARO and/or CROF must be up to date in their reporting in order to be eligible to apply for this program.
  13. Residents and fellows in radiation oncology who are members of CARO are welcome to apply. In the application form, please identify one of the co-investigators (C I) as the Co- PI, who will be mentoring the resident/fellow during the project. The mentoring Co-PI must be a CARO member in good standing at the time of application.

The 2024 award is administered by an Advisory Group chaired by Dr. Michael Kucharczyk. 

Each proposal should be submitted to the CARO head office in the ACURA application template

Deadline: Monday, May 27, 2024 at 5:00 PM EST

APPLY HERE

APPLIQUER MAINTENANTERE

x
The ACURA program was founded 23 years ago by AbbVie and CARO and, since 2001, the program has donated millions of dollars towards Canadian projects designed to advance prostate cancer treatments. The video above, which was developed in 2020 in celebration of ACURA’s 20th anniversary, provides a rich description of the ACURA awards program and its valuable contributions to research in Canada.   

Pour la version française, cliquez ici.

The ACURA (AbbVie – CARO Uro-Oncologic Radiation Award) program has enabled radiation oncology clinicians and researchers from across the country to make significant advances in the treatment of prostate cancer, thanks to the enduring partnership between CARO and AbbVie.

Congratulations 2023 ACURA Winners!

Enrique Gutierrez

Eric Vigneault

Maroie Barkati

Meredith Giuliani

Srinivas Raman